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Teaser  
This review will focus on currently available methods for the selection of the most suitable protein 
conformations for multi-target structure-based drug design. 
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Highlights  
 Structure-based approaches play a central role in polypharmacology drug design.  
 Similar protein conformations are able to accommodate similar ligands. 
 The use of selected protein conformations affects structure-based drug design results. 
 In silico approaches for protein conformation selection are presented. 
 Examples of protein conformation selection for structure-based drug design are reported. 
 
 
 
 
 
 
 
 
ABSTRACT  
Several drugs exert their therapeutic effect through the modulation of multiple targets. Structure-based 
approaches hold great promise for identifying compounds with the desired polypharmacological profiles. 
These methods employ the knowledge of the protein binding sites to identify stereoelectronically 
complementary ligands. The selection of the most suitable protein conformations to be used in the design 
process is of paramount importance, especially for multi-target drug design in which the same ligand has 
to be accommodated in multiple binding pockets. Herein, we will focus on currently available techniques 
for the selection of the most suitable protein conformations for multi-target drug design, compare 
potential advantages and limitations of each method, and comment on how their combination could help 
in polypharmacology drug design. 
 
Introduction 
The simultaneous modulation of multiple targets by means of a single drug, i.e., polypharmacology, is 
increasingly recognized as a valuable opportunity in drug discovery [1]. Several drugs are known to 
simultaneously bind to multiple biological targets, thus eliciting either unwanted side effects or beneficial 
synergistic activities [2]. However, designing drugs with a polypharmacological profile represents a 
challenging task [1,3,4] and the few examples of intended polypharmacology are usually within related 
protein families. However, recent efforts in predicting polypharmacology for distantly related targets 
have started to yield promising results [5–7]. Indeed, computational approaches have certainly proved to 
play a key role in exploiting the available structural information, and to perform de novo multi-target 
drug design and in silico profiling [8]. Moreover, a multitude of molecular modeling methods, which can 
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be broadly classified into structure- and ligand-based approaches, are currently available to aid in 
polypharmacology drug design [9,10].   
In general, structure-based methods allow the discovery of potentially active compounds according to 
their structural complementarity to a receptor, being molecular docking one of the most frequently used. 
In this context, the selection of the most suitable protein conformations to be used in a structure-based 
virtual screening (VS) campaign undoubtedly represents a challenging task. In fact, proteins are known 
to undergo significant conformational changes depending on the activation/inactivation state, catalytic 
activity, protein-protein interactions and binding of substrates or different modulators. Therefore, 
selected protein conformations and peculiar amino acid rearrangements induced by co-crystallization 
might bias the outcome of a structure-based drug design project [11,12]. Moreover, it has already been 
reported that: (i) better enrichments can be obtained in docking-based VS when the screened compounds 
are structurally similar to the co-crystallized ligands [13–15]; and (ii) the ability of structure-based 
methods (e.g., molecular docking) in discriminating active from inactive compounds is highly dependent 
on the used protein structure [14,16,17]. If this is not negligible in standard in silico structure-based drug 
discovery (i.e., the one drug – one target paradigm), this concept is even truer when designing molecules 
that are expected to simultaneously bind to more than one biological target.  
Importantly, the degree of similarity of the binding pockets of the studied targets is a critical aspect for 
the selection of protein conformations in a multi-target structure-based drug design project. In fact, it is 
well known that proteins with a high degree of binding site similarity are likely to bind similar ligands, 
as reported in drug repurposing or ligand promiscuity investigations [18,19]. Moreover, the more two 
proteins display similar binding sites and common interaction hot spots, the higher are the chances of 
identifying low molecular weight compounds that are stereoelectronically complementary to the targets 
under study. In the light of this, the selection of the most suitable protein conformations has a dramatic 
effect on in silico structure-based polypharmacology approaches, such as ligand profiling and de novo 
design. However, it has to be pointed out that the design of compounds with multi-target activity is also 
possible by developing ambivalent, chimeric ligands that bind head-to-tail in their respective protein 
targets. Nevertheless, these chimeric ligands usually have high molecular weight and unfavorable drug-
like properties.  
In this article, we will focus on the utility of different in silico approaches to select the most suitable 
protein conformations for structure-based multi-target drug design. This is still an emerging and largely 
unexplored topic. The following sections will provide the reader with an excursus of the currently 
available in silico approaches for protein conformation selection. A few illustrative examples will also 
be provided, demonstrating potential shortcomings and complementarities of the different approaches.  
 
In silico approaches for the selection of the most suitable protein conformations 
The selection of the most suitable protein conformations in multi-target drug design projects represents 
a challenging task, especially when the studied targets are structurally distant and belong to different 
protein families. However, medicinal chemistry data available from public repositories, which in the last 
decades have entered the so called “big data era” [20], could offer valuable opportunities for inferring 
new relationships between known modulators and different proteins. Indeed, several computational 
approaches have been successfully applied to identify potential activities of molecules on other targets, 
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e.g., on the basis of their structural similarity with already reported modulators [21,22]. At present, a 
variety of structure and ligand-based methods are available to analyze the wealth of information provided 
by public databases [23,24], and to guide the selection of the most suitable protein conformations for 
structure-based drug design [13,25].  
Ligand-based approaches in protein conformation selection 
Ligand-based methods enable the identification of new small-molecules through the knowledge of the 
structural details of known active and inactive compounds. Several approaches with different levels of 
abstraction (e.g., molecular descriptors, sets of bit-strings and spatial arrangements of pharmacophoric 
features) and algorithms allow encoding ligand properties and estimating the degree of similarity with 
respect to a reference compound [26,27]. Such methods could be profitably applied in protein 
conformation selection. In particular, conformations of different targets can be selected on the basis of 
the cross similarities of their ligands (Figure 1, panel a). For example, a recent study by Broccatelli F. et 
al. reported how ligand-based methods can be used to select the most suitable receptor conformations for 
a docking-based VS [13]. In this study, the authors compared the performance of different docking 
protocols (i.e., Glide HTVS, SP, and XP protocols) [28] in retrieving compounds active on the CDK2 
protein kinase (PK) within the ChEMBL [29,30] and Directory of Useful Decoys [31] datasets. In 
particular, they performed docking calculations by selecting CDK2 conformations on the basis of the 
similarity of the screened compounds with the co-crystallized ligands. The ligand-based analyses were 
performed by using the Pipeline Pilot Extended Connectivity Fingerprints (ECFP4) and the ROCS 
software that allowed taking into account the different aspects of the ligand similarity (i.e., chemical 
structure or shape and chemical pattern) [32,33]. The authors also suggested the use of multiple protein 
conformations in a VS to achieve higher hit rates. In fact, by combining docking to different CDK2 
conformations and ligand-based similarity approaches, Broccatelli F. et al. demonstrated that the more 
the screened compounds are structurally similar to the co-crystallized ligand in a given protein 
conformation, the higher are the hit rates obtained with docking [13]. Similar considerations to those 
argued by Broccatelli F. et al. can also be drawn by a more recent study proposed by Xu X. et al., in 
which  the authors were able to predict binding modes and affinities of a series of Hsp90 inhibitors [34]. 
Results were in good agreement with the experimental data and were obtained by docking the ligands to 
Hsp90 conformations selected on the basis of the similarity with the co-crystallized compounds. 
Moreover, this study also demonstrated that if a number of ligand-protein complexes are available for 
the target under study, significant improvements in binding mode prediction can be achieved by 
performing docking in conformations carefully selected on the basis of ligand similarity rather than 
through ensemble-based strategies, which use multiple protein conformations [34]. Similar 
improvements in binding mode prediction were also achieved by Duan R. et al. [35] that successfully 
implemented a workflow combining 3D ligand similarity evaluations for protein conformation selection 
and MD simulations of the obtained complexes to prospectively predict binding modes of a series of 
FXR ligands [35]. Despite the aforementioned studies were not aimed at identifying multi-target ligands, 
similar results, in principle, could be obtained when selecting the most suitable conformations of different 
proteins in multi-target projects, provided that the ligands co-crystallized with the two targets present 
overlapping pharmacophoric and/or structural features. In general, protein conformations in complex 
with the same inhibitor, or with similar ligands, should be preferred in polypharmacology studies. This 
rationale has been applied in the selection of protein conformations to get some insights into the 
mechanism of dual inhibition of a PI3K/mTOR dual inhibitor [36] and for prospective multi-target drug 
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design of dual p53-MDM2/MDMX interaction inhibitors [37]. However, the ability of ligands to bind to 
different biological targets by using separate chemical moieties (head-to-tail ligands) and/or adopting 
different conformations cannot be neglected [38,39].  
Ligand information derived by protein-ligand complexes has also been exploited for structure-based drug 
repositioning. In particular, Kalinina O.V. et al. [40] were able to predict thousands of known and 
unknown protein-drug interactions by first superimposing 3D structures of distant proteins in complex 
with a common active ligand and then, evaluating the structural complementarity of the newly identified 
cross protein-ligand complexes [40]. Even if this study did not focus on protein conformation selection, 
the obtained results highlighted the importance of selecting the most suitable protein conformations for 
drug repurposing. In particular, the identification of ligand-target associations with such a method was 
possible considering that: (i) proteins sharing a common ligand will likely accommodate other binders 
of the targets [40]; and (ii) cross protein-ligand compatibility can be appropriately evaluated using 
receptor conformations of the targets whose binding pockets present similarities and/or accommodate 
similar ligands. Interestingly, these considerations are, to some extent, in line with those reported in 
recent papers by Tyzack J.D. et al. and Das S. et al., in which the authors compared ligand-enzyme 
complexes from the PDB on the basis of the similarity of the bound ligands and discussed on how such 
results could be used to select the most relevant complexes for structure-based drug design [41,42]. 
Nevertheless, the selection of the most suitable protein conformations on the basis of the similarity of 
the co-crystallized ligands obviously presents some limitations. Firstly, it is possible only for those 
targets for which an adequate number of protein-ligand complexes are available [13]. Moreover, intrinsic 
limitations of ligand-based approaches should also be considered [43]. In addition, the identification of 
multi-target ligands structurally similar to that already co-crystallized might be unfavorable when 
searching for novel chemotypes, e.g., to avoid patent issues. On the other hand, several advantages can 
also be envisioned. In particular, if the structure of the identified hits is similar to those of the co-
crystallized ligands, the newly identified multi-target hits are less likely to be false positives [39]. In 
addition, structure-activity relationships of already reported crystallographic congeners might also help 
to identify which chemical moieties are important for the activity. However, one should be aware that 
the application of different ligand-based approaches in the similarity assessments may result in different 
protein conformation selections. In fact, different degree of similarity might be evaluated for the same 
pair of compounds on the basis of the chosen method (e.g., 2D vs. 3D ligand-based approaches). In this 
regard, a recent study by Chen et al., which reported an exhaustive analysis of a subset of the PDB 
structures by using different protein-centric and ligand-centric approaches, demonstrated that different 
performances in retrieving protein pairs sharing common ligands could be obtained according to the 
employed method [44]. Interestingly, the reported results allow to derive some guidelines for multi-target 
drug-design as well. In particular, they showed that 3D-based approaches outperformed 2D methods in 
retrieving structurally unrelated ligands and sequence unrelated proteins (but with similar binding sites), 
whereas 2D methods outperformed 3D ones in recognizing “obvious” structural relationships [44]. For 
the purpose of this review, these results could be reworded as follows: if the targets under study share a 
number of significantly similar co-crystallized ligands, 2D methods should be preferred for identifying 
the most suitable protein conformations for polypharmacology design. On the contrary, if available 
crystal structures of the targets are in complex with structurally unrelated ligands, 3D methods might 
help in identifying the most appropriate conformations. 
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Structure-based approaches in protein conformation selection 
A variety of protein-centered approaches might represent efficient tools to identify suitable protein 
conformations for polypharmacology studies [9,18,25,45]. In fact, the shape and properties of a binding 
site are mostly dependent on amino acid rearrangements, switches between active and inactive protein 
states, and the presence and chemical nature of the bound ligand. For example, the conformations of 
active and inactive states of PKs are known to be significantly different, leading to distant binding 
pockets. Selecting an active or an inactive PK conformation for polypharmacology ligand design would 
most likely lead to different sets of retrieved hits [46]. Moreover, PK structures may show additional 
allosteric pockets or sub-pockets that are not accessible in crystal structures with non-allosteric ligands.  
Binding site similarity evaluations allow the comparison of protein binding cavities [18]. Methods 
enabling the evaluation of the 3D similarity (on the basis of shape or geometrical similarities) between 
binding sites of structurally unrelated proteins have gained a considerable attention in medicinal 
chemistry, especially for the prediction of off-target activities [18,19]. Such methods allow the 
identification of binding pockets with similar anchoring points (or similar shapes) among different 
biological targets [18]. Moreover, they might also help identifying common “hot spots” across different 
targets derived by the presence of specific residues or water molecules involved into relevant H-bond 
networks that could explain ligand promiscuity [47]. Methods for 3D binding site similarity prediction 
have been successfully applied to assist polypharmacology-related tasks [18,48,49]. For example, 
BioGPS [50], which performs a binding site comparison by first detecting cavities in a given crystal 
structure, and, then, by evaluating the overlap in the molecular interaction fields (MIFs) between two 
different targets, allowed Siragusa L. et al. to unveil new potential target combinations for multi-target 
drug design [50]. In particular, the authors reported similarities between the binding site of the 
Sarcoplasmic Reticulum Ca2+ ion channel ATPase and the Estrogen Receptor alpha, even if the two 
proteins present a distant structural folding. Moreover, the authors also identified the structural 
determinants of sub-family selectivity in both the p38a/ERK2 and PPARα/PPARγ proteins [50]. 
Similarly, Niu M. et al. [51] identified Gefitinib as an inhibitor of β-secretase (BACE-1) by performing: 
(i) an extensive similarity analysis between BACE-1 and PK structures with the TM-align tool [52], 
which suggested the EGFR protein as one of the most structurally similar PKs to BACE-1; (ii) local 
binding site comparisons between BACE-1 and EGFR by using the SMAP software [53] further 
demonstrating that these proteins present a high local binding site similarity; and, finally, (iii) in vitro 
testing 13 FDA-approved drugs targeting EGFR on BACE-1 [51]. Combinations of different approaches 
for binding site comparisons have also successfully explained the promiscuity of ligands from a receptor-
based point of view, outperforming the use of a single method [47]. However, to the best of our 
knowledge, no systematic study has been performed so far to explore the possibility of identifying the 
most suitable protein conformations by means of binding site similarity in a multi-target drug design 
context. Given the potentialities of currently available binding site comparison methods, we believe that 
such approaches will play an important role for the selection of the most suitable protein conformations 
in future structure-based polypharmacology drug design. Sequence similarity-based methods have also 
been shown to be particularly efficient in identifying closely related targets, being often more efficient 
than 3D methods [44]. However, as the 3D coordinates of protein residues cannot be taken into account 
with such methods, they cannot be used for the protein conformation selection. 
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Although recent progresses in structural biology and crystal structure determination have increased the 
number of accessible protein conformations [54,55], the applicability of structure-based approaches to 
identify suitable receptor conformations accommodating similar ligands remains limited by the 
availability of 3D structures. Moreover, chosen criteria for the binding site definition (i.e., the residues 
selected for the binding site definition) may affect the final results. Interestingly, these methods could be 
used in combination with molecular dynamics (MD) to further explore the conformational space of the 
investigated binding cavity. MD is mainly used to: (i) describe the dynamic behavior of proteins at 
different timescales; (ii) understand the events occurring during the ligand-protein interaction process; 
and (iii) interpret the results of biophysical experiments and modeling studies [56,57]. However, MD 
approaches have also been applied in combination with the analyses of molecular descriptors, as 
molecular shape and volumes (POVME) [58], and statistical procedures (TRAPP) [59] to identify 
transient receptor conformations and help accounting for protein flexibility. Indeed, protein flexibility 
could strongly bias VS results [60,61] so that a variety of computational approaches has been developed 
to tackle this issue [62–66]. Combinations of MD and appropriate analysis tools could help exploring 
binding site flexibility, and thus obtaining representative structures, including alternative protein 
conformations such as different protein functional states, metastable intermediate conformations, and 
structures with transient pockets, to be employed for drug design [67]. For example, Osguthorpe D.J. et 
al. successfully performed MD simulations and binding site clustering to identify a subset of 
conformations of the Androgen Receptor for VS, thus improving database enrichment and the chemical 
diversity of the retrieved actives with respect to screening to a single conformation [64]. Moreover, the 
authors also applied the same binding site clustering approach on sets of HIV protease and CDK2 crystal 
structures, demonstrating that enrichments and ligand diversity can be also improved when docking is 
performed on conformational ensembles of crystallographic structures [64]. Structure-based approaches 
combining rigid receptor docking with protein structure modeling have also successfully overcome 
receptor flexibility issues [68] and have been applied to rationalize the selectivity of multi-target ligands. 
In particular, in a recent study of Selvam B. and coworkers, an application of MD simulations with 
Desmond [69] and probe mapping with the “multifragment” search module of the MOE2011.10 program 
[70] was used to address ligand selectivity [45]. In this study, the authors generated the conformational 
space of a set of similar bioaminergic G-protein-coupled receptors through MD, allowing the 
identification of common and distinct interaction “hot-spots” that were used to investigate selectivity 
and side effects. These features could be useful to guide the design of molecules able to circumvent 
metabolic side effects and pulmonary hypertension, which are commonly associated with antipsychotic 
drugs targeting bioaminergic receptors. Then, they performed retrospective docking screenings (with 
Glide) on a set of conformations of the different proteins that allowed to discriminate known ligands 
from decoys [28,45]. Despite its utility in single target drug design [67], MD has not been thoroughly 
explored for selecting protein conformations for polypharmacology studies. We envision that a 
combination of MD simulations (to generate an ensemble of protein conformations) and binding site 
comparisons (to assess binding site similarity of the generated conformations) could significantly 
increase the possibility of identifying overlapping conformations between two or more targets (Figure 
2).  
The combination of structure refinement, MD, binding energy predictions, and docking has also been 
proposed to account for protein flexibility and improve the docking accuracy [71–73]. In fact, it is well 
known that currently available docking algorithms might provide inaccurate binding energy estimations 
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[74] as they might not properly account for entropic and solvation terms [75]. Therefore, the use of more 
accurate scoring methods has been explored. In this context Greenidge P.A. et al. demonstrated that 
advanced workflows, including combinations of MM-GBSA binding free energy rescoring and docking, 
improved pose prediction and binding affinity estimations in a VS [76]. However, it should be noted that 
such methods might present intrinsic limitations, one of them being the computational cost. More 
recently, scoring functions (SC) based on machine-learning approaches have also been developed. For 
example, Wójcikowski M. et al. have recently reported a scoring function (RF-Score-VS) based on the 
machine-learning random forest approach [77]. They also demonstrated that machine-learning based SC 
could exceed classical SC in correctly scoring training set compounds across different biological targets 
[77]. Similar results were also achieved by Kinnings S.L. et al. in  the drug repurposing field, where they 
successfully applied a classification support vector machine approach to improve SC performance in 
docking [78]. In particular, the authors were able to identify Phosphodiesterase (PDE) inhibitors with 
potential activity on InhA, a recognized target for treating Mycobacterium Tuberculosis infections. 
Moreover, the authors were also able to prioritize a set of compounds known to bind to estrogen-like 
receptors, further confirming the ability of machine-learning based SC in predicting binding affinity [78]. 
Despite the potentialities of machine-learning approaches in drug discovery, applications in protein 
conformation selection have not yet been reported. 
Molecular docking can be considered as well a useful tool for the selection of the most suitable protein 
conformations for structure-based VSs. In this regard, a recent study of Wang et al. reported how 
integration of molecular docking and statistical analysis could help in identifying the most suitable 
protein conformations for structure-based drug design [25]. In particular, the authors investigated 249 
protein structures of 14 autophagy-related targets by using Surflex-dock [79]. Then, they prioritized 
protein conformations on the basis of their ability to distinguish active ligands from inactive ones 
evaluated in terms of docking score distributions. However, as also stated by the authors, the applicability 
of this methodology strongly depends on the availability of active and inactive ligands for the target 
under study [25]. Therefore, the applicability of docking-based protein conformation selection in 
polypharmacology design requires an adequate number of known inhibitors for all the targets under 
study. More recently, Jaiteh M. et al. have reported the identification of novel dual-target ligands of 
A2AAR and MAO-B by means of docking screenings [80]. In particular, the authors performed first 
parallel validations of a series of A2AAR and MAO-B docking protocols, without focusing on structures 
of already reported dual inhibitors to avoid potential biases in the prospective screening. This allowed 
the identification of structurally distant protein conformations of the two targets, providing the best 
logAUC on a training set of ligands. Then, they carried out structure-based VS, prioritizing screening 
compounds on the basis of a consensus rank on the two targets. Thanks to this approach, Jaiteh M. et al. 
identified two nanomolar dual inhibitors of A2AAR and MAO-B. However, subsequent structure-activity 
relationship studies did not provide improvements of the dual activity profiles, as even slight 
modifications of the identified scaffolds negatively affected the activity toward one target or the other. 
Therefore, these results provided some insights into the use of docking methods for selecting the suitable 
protein conformations for multi-target drug design.  
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Concluding Remarks and Future Perspectives 
Structure-based methods represent essential tools for designing multi-target ligands. Despite a variety of 
methods and algorithms are currently available to estimate the complementarity of ligands with the 
binding site of the targets under study, the selection of the proper protein conformations is still of 
paramount concern. In fact, it is well known that structure-based VS results are strongly dependent on 
the used protein conformation and that structural details or peculiarities in the selected binding sites may 
allow potential biases toward the identification of certain chemical scaffolds instead of others [13,14]. 
These issues become even more relevant in polypharmacology applications, even if they have received 
very little attention so far. However, the information provided by available protein-ligand complexes, 
which allows encoding key receptor-ligand interactions and anchoring points of a protein binding site, 
should be always taken into account when performing polypharmacology structure-based drug design. 
Several approaches have been proposed to partially overcome potential pitfalls related to the use of a 
single receptor conformation in standard VS. In particular, methods based on the use of an ensemble of 
protein conformations and docking algorithms incorporating receptor flexibility in the calculations have 
demonstrated to provide higher hit rates with respect to the use of a single protein conformation 
[65,66,81–84]. In multi-target drug design, considering an ensemble of protein conformations may 
increase the chances of retrieving compounds with dual activity, as a consequence of the higher 
probability of identifying conformations of the two targets sharing common anchor points. Moreover, 
the selection of appropriate protein conformations becomes even more relevant when the two targets 
display low similarities because of the presence of water molecules in the binding site. In such cases, the 
importance of specific water molecules for ligand binding should be carefully assessed a priori in order 
to: (i) avoid including in the binding site thermodynamically unfavorable waters (potentially replaceable 
by the inhibitors) and; (ii) retain those involved in highly conserved H-bond networks. In this regard, the 
reported protein-ligand complexes may allow the identification of conserved water-mediated protein-
ligand interactions that cannot be neglected in the ligand design process [85]. However, even though 
several drug design applications have been reported [86,87], this issue has not yet been thoroughly 
considered in multi-target drug design.  
In general, binding site conformations of the different targets should be selected by trying to: (i) limit 
biases on compound selection derived by the use of peculiar protein conformations, which may represent 
low populated protein states; and (ii) identify, either by ligand similarity or binding site comparison 
techniques, protein conformations able to accommodate compounds with similar scaffolds. Therefore, 
selecting multiple conformations across different targets to enable structure-based drug design represents 
a challenging task. However, a number of ligand- and structure-based approaches are available to analyze 
the wealth of information provided by publicly available databases of either protein-ligand complexes or 
apo structures [9]. Moreover, the combination of different computational approaches could allow to 
thoroughly exploit information derived by the structural details of both co-crystallized ligands and 
residues lining the binding site. In particular, when an adequate number of structures of protein-ligand 
complexes are available, structure- and ligand-based analyses can be performed in parallel to guide the 
selection of protein conformations. Such approaches may allow the identification of several pairs of 
protein conformations with sufficient similarity to be used in docking. For example, ligand-based 
similarity approaches on the co-crystallized ligands could help in identifying pairs of protein 
conformations able to accommodate similar compounds, whereas structure-centered approaches might 
allow the identification of common anchoring points or similar structural features shared by different 
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protein cavities. These latter approaches are especially useful when dealing with apo structures. In the 
same line, molecular dynamics techniques combined with binding site comparison tools, machine-
learning approaches, analyses of molecular descriptors, etc. may also allow to sample the conformational 
landscape of proteins, thus enabling the use of alternative protein conformations for multi-target ligand 
design [67]. Overall, even if it received very little attention in polypharmacology so far, the selection of 
protein conformations operated upon these considerations will likely provide structure-based models 
with improved forecasting performances, thus creating novel opportunities for future multi-target drug 
design. 
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Figure Legends 
Figure 1. Ligand-based methods can be used to select the most suitable protein conformations to be used 
in structure-based multi-target drug design. Panel a) shows that ligands extracted from the complexes in 
their crystallographic conformations can be used to identify pairs of ligands (and, therefore, pairs of 
protein conformations) for the subsequent VS. Different approaches can be used for the assessment of 
the ligand similarity. Moreover, the identified ligand cross-similarities could also be used, in principle, 
to prescreen a database of ligands in a VS campaign - Panel b). 
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Figure 2. Structure-based approaches can be used to compare the binding site of different protein 
conformations or validate screening protocols, when an appropriate number of crystal structures 
conformation is available for the targets under study. These analyses could allow the identification of 
protein conformations across different targets that are able to accommodate the same ligands. Moreover, 
molecular dynamics simulations can be used to further sample the protein conformational space. The 
identified pairs of protein conformations can then be used in a parallel structure-based VS workflow to 
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increase the chances of identifying multi-target inhibitors, either as a single conformation per target or 
as ensembles. 
 
 
 
